We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ICER

News List

Big Pharma's antibody drugs for asthma show benefits but cost 50% too much: ICER fiercepharma
September 28, 2018
New antibody-based treatments are better than traditional drugs for moderate to severe asthma, but they still cost too much, a U.S. drug cost watchdog says. More than 50% too much, in fact.
Big Pharma's antibody drugs for asthma show benefits but cost 50% too much: ICER fiercepharma
September 27, 2018
New antibody-based treatments are better than traditional drugs for moderate to severe asthma, but they still cost too much, a U.S. drug cost watchdog says. More than 50% too much, in fact.
‘Sham’ or public interest? ICER suggests 70%-plus discounts on Vertex’s cystic fibrosis drugs fiercepharma
May 07, 2018
Vertex has often talked about its admiration of Gilead, setting the big biotech’s ability to roll out multiple antivirals as a model for its cystic fibrosis endeavor. Now, though...

Previous page 1 2 Next page